5 Big Drug Stocks That May Continue to Outperform in 2026

Key Takeaways Large-cap pharma has beaten the S&P 500 lately as pricing deals, M&A and innovation revive investor sentiment.Eli Lilly, J&J, AbbVie, Amgen and AstraZeneca all posted strong 2025 gains on key drugs and pipeline. Despite patent cliffs and regulatory risks, innovation, AI use and deal momentum support a solid 2026 outlook.After a weak first half, the drug and biotech sector has recovered in the past 2-3 months, with most large drugmakers signing drug pricing agreements with the Trump administrat ...